Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new? The Type 2 Diabetes Knowledge Centre

Based on current estimates, the global prevalence of type 2 diabetes has increased almost 10 fold since 1985 and is expected to rise to 552 million by 2030,1 and when absolute numbers of people with diabetes are considered, it is South East Asia and the West Pacific that are expected to experience the highest increases in prevalence over the coming years.2

Type 2 diabetes can be defined according to fasting plasma glucose (FPG) and 2 hour plasma glucose levels. The first is assessed after 8-10 hours of fasting, usually in the morning. The second is measured by an oral glucose tolerance test (OGTT) assessing venous plasma glucose 2 hour after ingestion of a 75g oral glucose load.

Type 2 Diabetes involves two primary pathogenic mechanisms; insulin resistance and impaired insulin secretion. Insulin resistance occurs when the insulin in the body does not exert sufficient action proportional to its blood concentration.3,4 Impaired insulin secretion is characterised by decreased glucose responsiveness, and is observed before the clinical onset of disease.4

Latest News

FDA approves Vimpat monotherapy in Epilepsy-UCB

02-Sep-2014

UCB announced that the FDA has ...

Four Phase III trials of SAR 236553 meet endpoints for Hypercholesterolemia-Sanofi/Regeneron

02-Sep-2014

Sanofi and Regeneron Pharmaceuticals ...

FDA approves Viva CRT-P pacemaker for Heart Failure and AV Block - Medtronic

01-Sep-2014

Medtronic, Inc. has announced the FDA ...

Alkermes Plc files once-monthly, long-acting aripiprazole lauroxil at FDA for Schizophrenia

01-Sep-2014

Alkermes plc has announced that it ...

Medtronic has 510 (k) clearance for SHILLA Growth Guidance System to treat Spinal Deformities,

31-Aug-2014

Medtronic, Inc. has announced the ...

TA 8995 (DEZ 001) positive in Phase IIb trial for treatment of Dyslipidaemia - Dezima Pharma

31-Aug-2014

Dezima Pharma has announced that it ...

Positive results in study of LCZ 696 for Heart Failure - Novartis

31-Aug-2014

Data from a Phase III trial shows ...

Recent Updates

Drugs

Clinical Guidelines

Hypertension in pregnancy. The management of hypertensive disorders during pregnancy

Diagnosis and management of acute graft-versus-host disease

Guidelines for the pharmacological treatment of anxiety disorders, obsessive – compulsive disorder and posttraumatic stress disorder in primary care

Inflammatory bowel disease biopsies: updated British Society of Gastroenterology reporting guidelines

Medical Journals

Short Course Adjuvant Terlipressin in Acute Variceal Bleed: A Randomized Double Blind Dummy Controlled Trial

The Pharmacokinetics and Pharmacogenetics of the Antiemetic Cyclizine in Palliative Care Patients

Paucity of evidence regarding urinary tract outcomes in closed spinal dysraphism: a systematic review.

Customizing Anaphylaxis Guidelines for Emergency Medicine

epgonline.org Social